LATISSE ® (bimatoprost ophthalmic solution) 0.03% is supplied sterile in opaque white low density polyethylene dispenser bottles and tips with turquoise polystyrene caps accompanied by sterile, disposable applicators:
3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70
5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05
Storage: Store at 2º to 25ºC (36º to 77ºF).
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform patients that LATISSE ® (bimatoprost ophthalmic solution) should be applied every night using only the accompanying sterile applicators. They should start by ensuring their face is clean, all makeup is removed, and their contact lenses removed (if applicable). Then, carefully place one drop of LATISSE ® solution on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. If any LATISSE ® solution gets into the eye proper, it will not cause harm. The eye should not be rinsed.
Additional applications of LATISSE ® will not increase the growth of eyelashes.
Inform patients not to apply to the lower eyelash line. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material.
The onset of effect is gradual but is not significant in the majority of patients until 2 months. Counsel patients that the effect is not permanent and can be expected to gradually return to the original level upon discontinuation of treatment with LATISSE ® .
Handling the Bottle and Applicator
Instruct patients that the LATISSE ® bottle must be maintained intact and to avoid allowing the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination of the bottle or applicator by common bacteria known to cause ocular infections. Instruct patients to only use the applicator supplied with the product once and then discard since reuse could result in using a contaminated applicator. Serious infections may result from using contaminated solutions or applicators.
Potential for Intraocular Pressure Effects
LATISSE ® may lower intraocular pressure although not to a level that will cause clinical harm.
In patients using LUMIGAN ® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE ® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs for IOP reduction should only use LATISSE ® after consulting with their physician.
Potential for Eyelid Skin Darkening
Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of LATISSE ® .
Potential for Iris Darkening
Advise patients about the potential for increased brown iris pigmentation which is likely to be permanent. Increased iris pigmentation has occurred when bimatoprost solution was administered.
Potential for Unexpected Hair Growth or Eyelash Changes
Inform patients of the possibility of hair growth occurring outside of the target treatment area if LATISSE ® repeatedly touches the same area of skin outside the treatment area. They should also be informed of the possibility of disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are likely reversible upon discontinuation of treatment.
When to Seek Physician Advice
Advise patients that if they develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of LATISSE ® . Patients on IOP-lowering medications should not use LATISSE ® without prior consultation with their physician.
Contact Lens Use
Advise patients that LATISSE ® solution contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to application of LATISSE ® and may be reinserted 15 minutes following its administration.
Allergan USA, Inc.
Madison, NJ 07940
© 2020 Allergan. All rights reserved.
All trademarks are the property of their respective owners.
Patented. See: www.allergan.com/patents
FDA-approved Patient Labeling
LATISSE ® [la teece]
(bimatoprost ophthalmic solution) 0.03%
Read the Patient Information that comes with LATISSE ® before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your physician about your treatment.
What is hypotrichosis of the eyelashes?
Hypotrichosis is another name for having inadequate or not enough eyelashes.
What is LATISSE ® solution?
LATISSE ® solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.
Who should NOT take LATISSE ® ?
Do not use LATISSE ® solution if you are allergic to one of its ingredients.
Are there any special warnings associated with LATISSE ® use?
LATISSE ® solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. Refer to Illustration 2 below. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN ® or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE ® under the close supervision of your physician.
LATISSE ® use may cause darkening of the eyelid skin which may be reversible. LATISSE ® use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.
It is possible for hair growth to occur in other areas of your skin that LATISSE ® frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE ® .
Who should I tell that I am using LATISSE ® ?
You should tell your physician you are using LATISSE ® especially if you have a history of eye pressure problems.
You should also tell anyone conducting an eye pressure screening that you are using LATISSE ® .
What should I do if I get LATISSE ® in my eye?
LATISSE ® solution is an ophthalmic drug product. LATISSE ® is not expected to cause harm if it gets into the eye proper. Do not attempt to rinse your eye in this situation.
What are the possible side effects of LATISSE ® ?
The most common side effects after using LATISSE ® solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE ® solution may cause other less common side effects which typically occur on the skin close to where LATISSE ® is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your physician’s advice concerning the continued use of LATISSE ® solution.
What happens if I stop using LATISSE ® ?
If you stop using LATISSE ® , your eyelashes are expected to return to their previous appearance over several weeks to months.
Any eyelid skin darkening is expected to reverse after several weeks to months.
Any darkening of the colored part of the eye known as the iris is NOT expected to reverse and is likely permanent.
How do I use LATISSE ® ?
The recommended dosage is one application nightly to the skin of the upper eyelid margin at the base of the eyelashes only.
Once nightly, start by ensuring your face is clean, makeup and contact lenses are removed. Remove an applicator from its tray. Then, holding the sterile applicator horizontally, place one drop of LATISSE ® on the area of the applicator closest to the tip but not on the tip (see Illustration 1). Then immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part (see Illustration 2). Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use.
Repeat for the opposite upper eyelid margin using a new sterile applicator. This helps minimize any potential for contamination from one eyelid to another.
DO NOT APPLY in your eye or to the lower lid. ONLY use the sterile applicators supplied with LATISSE ® to apply the product. If you miss a dose, don’t try to “catch up.” Just apply LATISSE ® solution the next evening. Fifty percent of patients treated with LATISSE ® in a clinical study saw significant improvement by 2 months after starting treatment.
If any LATISSE ® solution gets into the eye proper, it is not expected to cause harm. The eye should not be rinsed.
Don’t allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination by common bacteria known to cause infections.
Contact lenses should be removed prior to application of LATISSE ® and may be reinserted 15 minutes following its administration.
Use of LATISSE ® more than once a day will not increase the growth of eyelashes more than use once a day.
Store LATISSE ® solution at 36o to 77o F (2o to 25o C).
General Information about LATISSE ®
Prescription treatments are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LATISSE ® solution for a condition for which it was not prescribed. Do not give LATISSE ® to other people. It may not be appropriate for them to use.
This leaflet summarizes the most important information about LATISSE ® solution. If you would like more information, talk with your physician. You can also call Allergan’s product information department at 1-800-678-1605.
What are the ingredients in LATISSE ® ?
Active ingredient: bimatoprost
Inactive ingredients: benzalkonium chloride; sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 — 7.8.
Allergan USA, Inc.
Madison, NJ 07940
© 2020 Allergan. All rights reserved.
All trademarks are the property of their respective owners. Patented. See: www.allergan.com/patents
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.